Exploring Acceptability Drivers of Oral Antibiotics in Children: Findings from an International Observational Study.
ClinSearch acceptability score test (CAST)
acceptability
antibiotic
children
formulation
pediatric
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
18 Oct 2021
18 Oct 2021
Historique:
received:
24
08
2021
revised:
08
10
2021
accepted:
12
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Antibiotics are among the most commonly prescribed drugs in children. Adherence to the treatment with these drugs is of the utmost importance to prevent the emergence of resistant bacteria, a global health threat. In children, medicine acceptability is likely to have a significant impact on compliance. Herein we used a multivariate approach, considering simultaneously the many aspects of acceptability to explore the drivers of oral antibiotic acceptability in children under twelve, especially in toddlers and in preschoolers. Based on 628 real-life observer reports of the intake of 133 distinct medicines, the acceptability reference framework highlighted the influence of many factors such as age and sex of patients, previous exposure to treatment, place of administration, administration device, flavor agent in excipients and active pharmaceutical ingredient. These findings from an international observational study emphasize the multidimensional nature of acceptability. Therefore, it is crucial to consider all these different aspects for assessing this multi-faceted concept and designing or prescribing a medicine in order to reach adequate acceptability in the target population.
Identifiants
pubmed: 34684014
pii: pharmaceutics13101721
doi: 10.3390/pharmaceutics13101721
pmc: PMC8537532
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antibiotics (Basel). 2019 May 02;8(2):
pubmed: 31052566
Pediatr Infect Dis J. 1994 Aug;13(8):686-90
pubmed: 7970967
Pharmaceutics. 2021 Mar 06;13(3):
pubmed: 33800757
Eur J Pediatr. 2009 Jul;168(7):851-7
pubmed: 18958497
BMC Geriatr. 2019 Dec 7;19(1):344
pubmed: 31810442
J Pharm Pharmacol. 2018 Jan;70(1):42-50
pubmed: 29072321
Lancet Infect Dis. 2005 Aug;5(8):481-93
pubmed: 16048717
Pediatrics. 2014 Mar;133(3):375-85
pubmed: 24488744
J Pharm Pharmacol. 2017 Apr;69(4):406-416
pubmed: 27109018
Arch Pediatr Adolesc Med. 2000 Mar;154(3):267-70
pubmed: 10710025
Int J Pharm. 2015 Aug 1;491(1-2):261-7
pubmed: 26143234
Scand J Prim Health Care. 1987 Nov;5(4):241-3
pubmed: 3321313
Pediatr Infect Dis J. 1996 Jan;15(1):18-22
pubmed: 8684871
Appetite. 2008 Mar-May;50(2-3):181-93
pubmed: 17997196
Int J Pharm. 2011 Aug 30;415(1-2):221-31
pubmed: 21640807
Arch Pediatr. 2011 May;18(5):611-6
pubmed: 21420838
Scand J Prim Health Care. 1989 Jun;7(2):87-92
pubmed: 2511611
Pharmaceutics. 2021 Feb 23;13(2):
pubmed: 33672395
Eur J Pediatr. 1984 Feb;141(4):243-7
pubmed: 6734676
Eur J Clin Pharmacol. 1986;30(4):503-4
pubmed: 3091373
Pharmaceutics. 2019 Aug 01;11(8):
pubmed: 31374869
Int J Pharm. 2015 Aug 15;492(1-2):304-15
pubmed: 26002569
Sci Pharm. 2015 Jul 01;83(3):511-8
pubmed: 26839835
JAMA. 2018 May 15;319(19):2009-2020
pubmed: 29800213
Lancet Infect Dis. 2019 Jan;19(1):67-75
pubmed: 30522834
Antimicrob Resist Infect Control. 2017 May 15;6:47
pubmed: 28515903
J Pediatr. 2017 Mar;182:239-244.e1
pubmed: 28012694
Arch Dis Child. 2012 Mar;97(3):293-7
pubmed: 22088684
Pediatr Infect Dis J. 2015 Feb;34(2):e16-22
pubmed: 25144795
South Med J. 1990 Oct;83(10):1174-7
pubmed: 2218657
Clin Epidemiol. 2014 Apr 01;6:111-8
pubmed: 24729727
Drug Discov Today. 2021 Feb;26(2):329-343
pubmed: 33217597
Pediatr Infect Dis J. 1997 Feb;16(2 Suppl):S21-4
pubmed: 9041624
PLoS One. 2019 Aug 20;14(8):e0221261
pubmed: 31430323
Pharmaceutics. 2020 Aug 13;12(8):
pubmed: 32823568
Bull World Health Organ. 2020 Jul 1;98(7):458-466
pubmed: 32742031